1. Soluble TIM-3 as a biomarker of progression and therapeutic response in cancers and other of human diseases;Bailly C;Biochemical pharmacology,2023
2. Cao, W., Li, M., Liu, J., Zhang, S., Noordam, L., Verstegen, M. M. A., Wang, L., Ma, B., Li, S., Wang, W., Bolkestein, M., Doukas, M., Chen, K., Ma, Z., Bruno, M., Sprengers, D., Kwekkeboom, J., van der Laan, L. J. W., Smits, R., Peppelenbosch, M. P., and Pan, Q. (2020). LGR5 marks targetable tumor-initiating cells in mouse liver cancer. Nature communications 11: 1961.
3. Advancing the understanding of NAFLD to hepatocellular carcinoma development: From experimental models to humans;Chen K;Biochimica et biophysica acta Reviews on cancer,2019
4. Clinical Value of Combined Detection of Serum sTim-3 and Pepsinogen for Gastric Cancer Diagnosis;Chen L;Cancer management and research,2021
5. Clinical value of the sTim–3 level in chronic kidney disease;Chen L;Experimental and therapeutic medicine,2022